A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
A deal with Jacobio is worth $100m up front.
The private ADC company is being wound down.
Two new PD-(L)1 x VEGF projects have entered the clinic.
